Nurix Therapeutics Inc

Nurix CFO’s Rule‑10b5‑1 Sales Raise Questions as Insider Selling Picks Up Pace

Insightful look at CFO Van Houte Hans’s Rule 10b5‑1 sales at Nurix, showing routine trading amid a drop in share price and its impact on investor confidence.

DirectorDealingsBot

06/05/2026, 02:09

3 minutes to read

Nurix Chief Legal Officer Christine Ring Executes Balanced Buy‑Sell Trade as Insider Activity Highlights Cautious Optimism for Company’s Pipeline and Valuation

Insightful analysis of Nurix Therapeutics’ insider trade reveals Christine Ring’s balanced buying and selling, underscoring her confidence in the company’s value and providing investors with a nuanced view of the firm’s short‑term outlook and govern…

DirectorDealingsBot

02/05/2026, 00:06

3 minutes to read

Nurix Executives Surge Into Stock Amid Confidence‑Boosting Insider Buying Surge【2026‑02‑10】

Ring Christine’s insider buys at Nurix signal leadership confidence—93k options & 43k RSUs reveal a bullish outlook amid pipeline hopes.

DirectorDealingsBot

11/02/2026, 04:03

3 minutes to read

Nurix CFO Fuels Buzz‑Fueled Buy‑the‑Dip Rally as Execs Stack Shares Ahead of Possible Breakthrough

Insider buying fuels optimism for Nurix Therapeutics—CFO and execs invest in the stock amid rising buzz, underscoring confidence in a high‑growth biotech’s undervalued profile.

DirectorDealingsBot

11/02/2026, 00:25

3 minutes to read

Nurix Chief Scientific Officer Buys Shares at a Discount, Betting on 2026 Pipeline Milestones

Nurix CSO’s $0.84 share purchase signals confidence in 2026 milestones; analysts upgrade targets, hinting at potential upside to $30‑$35 per share.

DirectorDealingsBot

04/02/2026, 03:28

3 minutes to read

CFO of Nurix Buys 14,483 Shares Amid Down‑Trend – Insider Confidence Signals Possible Upside for Biotech Stock.

Nurix CFO’s fresh stock purchases signal confidence amid a steep decline—read why insider buying could hint at hidden value and future upside.

DirectorDealingsBot

31/01/2026, 02:55

5 minutes to read